Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis
- PMID: 9573066
- PMCID: PMC108140
- DOI: 10.1128/IAI.66.5.1891-1897.1998
Synthesis and characterization of lipooligosaccharide-based conjugates as vaccine candidates for Moraxella (Branhamella) catarrhalis
Abstract
Moraxella (Branhamella) catarrhalis is an important cause of otitis media and sinusitis in children and of lower respiratory tract infections in adults. Lipooligosaccharide (LOS) is a major surface antigen of the bacterium and elicits bactericidal antibodies. Treatment of the LOS from strain ATCC 25238 with anhydrous hydrazine reduced its toxicity 20,000-fold, as assayed in the Limulus amebocyte lysate (LAL) test. The detoxified LOS (dLOS) was coupled to tetanus toxoid (TT) or high-molecular-weight proteins (HMP) from nontypeable Haemophilus influenzae through a linker of adipic acid dihydrazide to form dLOS-TT or dLOS-HMP. The molar ratios of dLOS to TT and HMP conjugates were 19:1 and 31:1, respectively. The antigenicity of the two conjugates was similar to that of the LOS, as determined by double immunodiffusion. Subcutaneous or intramuscular injection of both conjugates elicited a 50- to 100-fold rise in the geometric mean of immunoglobulin G (IgG) to the homologous LOS in mice after three injections and a 350- to 700-fold rise of anti-LOS IgG in rabbits after two injections. The immunogenicity of the conjugate was enhanced by formulation with monophosphoryl lipid A plus trehalose dimycolate. In rabbits, conjugate-induced antisera had complement-mediated bactericidal activity against the homologous strain and heterologous strains of M. catarrhalis. These results indicate that a detoxified LOS-protein conjugate is a candidate for immunization against M. catarrhalis diseases.
Figures



Similar articles
-
Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.Vaccine. 2011 Jun 6;29(25):4210-7. doi: 10.1016/j.vaccine.2011.03.102. Epub 2011 Apr 16. Vaccine. 2011. PMID: 21501641 Free PMC article.
-
Synthesis, characterization, and immunologic properties of detoxified lipooligosaccharide from nontypeable Haemophilus influenzae conjugated to proteins.Infect Immun. 1996 Oct;64(10):4047-53. doi: 10.1128/iai.64.10.4047-4053.1996. Infect Immun. 1996. PMID: 8926067 Free PMC article.
-
Synthesis and characterization of lipooligosaccharide-based conjugate vaccines for serotype B Moraxella catarrhalis.Infect Immun. 2005 May;73(5):2790-6. doi: 10.1128/IAI.73.5.2790-2796.2005. Infect Immun. 2005. PMID: 15845482 Free PMC article.
-
Progress toward the development of a vaccine to prevent Moraxella (Branhamella) catarrhalis infections.Microbes Infect. 2000 Apr;2(5):561-8. doi: 10.1016/s1286-4579(00)00310-5. Microbes Infect. 2000. PMID: 10865201 Review.
-
Vaccines for Moraxella catarrhalis.Vaccine. 2000 Dec 8;19 Suppl 1:S101-7. doi: 10.1016/s0264-410x(00)00287-5. Vaccine. 2000. PMID: 11163472 Review.
Cited by
-
Isolation and characterization of two proteins from Moraxella catarrhalis that bear a common epitope.Infect Immun. 1998 Sep;66(9):4374-81. doi: 10.1128/IAI.66.9.4374-4381.1998. Infect Immun. 1998. PMID: 9712790 Free PMC article.
-
Mutant lipooligosaccharide-based conjugate vaccine demonstrates a broad-spectrum effectiveness against Moraxella catarrhalis.Vaccine. 2011 Jun 6;29(25):4210-7. doi: 10.1016/j.vaccine.2011.03.102. Epub 2011 Apr 16. Vaccine. 2011. PMID: 21501641 Free PMC article.
-
Bactericidal monoclonal antibody against Moraxella catarrhalis lipooligosaccharide cross-reacts with Haemophilus Spp.Curr Microbiol. 2007 Feb;54(2):85-90. doi: 10.1007/s00284-005-0463-6. Epub 2007 Jan 5. Curr Microbiol. 2007. PMID: 17211546
-
Late acyltransferase genes lpxX and lpxL jointly contribute to the biological activities of Moraxella catarrhalis.J Med Microbiol. 2013 Jun;62(Pt 6):807-812. doi: 10.1099/jmm.0.056846-0. Epub 2013 Mar 8. J Med Microbiol. 2013. PMID: 23475908 Free PMC article.
-
Specific immune responses and enhancement of murine pulmonary clearance of Moraxella catarrhalis by intranasal immunization with a detoxified lipooligosaccharide conjugate vaccine.Infect Immun. 2002 Nov;70(11):5982-9. doi: 10.1128/IAI.70.11.5982-5989.2002. Infect Immun. 2002. PMID: 12379673 Free PMC article.
References
-
- Ahmed K, Rikitomi N, Ichinose A, Matsumoto K. Possible presence of a capsule in Branhamella catarrhalis. Microbiol Immunol. 1991;35:361–366. - PubMed
-
- Alaeus, A., and G. Stiernstedt.Branhamella catarrhalis septicemia in an immunocompetent adult. Scand. J. Infect. Dis. 23:115–116. - PubMed
-
- Bluestone, C. D. 1986. Otitis media and sinusitis in children. Role of Branhamella catarrhalis. Drugs 31(Suppl. 3):132–141. - PubMed
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Molecular Biology Databases